RT Journal Article
T1 Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.
A1 Martinez-Martinez, Laura
A1 Lleixà, Ma Cinta
A1 Boera-Carnicero, Gemma
A1 Cortese, Andrea
A1 Devaux, Jérôme
A1 Siles, Ana
A1 Rajabally, Yusuf
A1 Martinez-Piñeiro, Alicia
A1 Carvajal, Alejandra
A1 Pardo, Julio
A1 Delmont, Emilien
A1 Attarian, Shahram
A1 Diaz-Manera, Jordi
A1 Callegari, Ilaria
A1 Marchioni, Enrico
A1 Franciotta, Diego
A1 Benedetti, Luana
A1 Lauria, Guiseppe
A1 de la Calle Martin, Oscar
A1 Juárez, Cándido
A1 Illa, Isabel
A1 Querol, Luis
K1 Antibodies
K1 CIDP
K1 HLA DRB1*15
K1 NF155
AB The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.
YR 2017
FD 2017-11-16
LK http://hdl.handle.net/10668/11806
UL http://hdl.handle.net/10668/11806
LA en
DS RISalud
RD Apr 18, 2025